Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 2 |
2020 | 6 |
2021 | 2 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
Page 1
Combination of targeted daunorubicin liposomes and targeted emodin liposomes for treatment of invasive breast cancer.
J Drug Target. 2020 Mar;28(3):245-258. doi: 10.1080/1061186X.2019.1656725. Epub 2019 Sep 2.
J Drug Target. 2020.
PMID: 31462111
Review.
Enhanced antitumour efficacy of functionalized doxorubicin plus schisandrin B co-delivery liposomes via inhibiting epithelial-mesenchymal transition.
Cai FY, Yao XM, Jing M, Kong L, Liu JJ, Fu M, Liu XZ, Zhang L, He SY, Li XT, Ju RJ.
Cai FY, et al.
J Liposome Res. 2021 Jun;31(2):113-129. doi: 10.1080/08982104.2020.1745831. Epub 2020 Apr 13.
J Liposome Res. 2021.
PMID: 32200703
Item in Clipboard
Dual variable of drug loaded micelles in both particle and electrical charge on gastric cancer treatment.
Li XY, Wang JH, Gu LY, Yao XM, Cai FY, Jing M, Li XT, Ju RJ.
Li XY, et al. Among authors: cai fy.
J Drug Target. 2020 Dec;28(10):1071-1084. doi: 10.1080/1061186X.2020.1777419. Epub 2020 Jun 19.
J Drug Target. 2020.
PMID: 32484364
Item in Clipboard
GGP modified daunorubicin plus dioscin liposomes inhibit breast cancer by suppressing epithelial-mesenchymal transition.
Yao XM, Niu FJ, Kong L, Cai FY, Jing M, Fu M, Liu JJ, He SY, Zhang L, Liu XZ, Ju RJ, Li XT.
Yao XM, et al. Among authors: cai fy.
Drug Dev Ind Pharm. 2020 Jun;46(6):916-930. doi: 10.1080/03639045.2020.1763397. Epub 2020 May 18.
Drug Dev Ind Pharm. 2020.
PMID: 32362146
Item in Clipboard
Development of R8 modified epirubicin-dihydroartemisinin liposomes for treatment of non-small-cell lung cancer.
Liu JJ, Tang W, Fu M, Gong XQ, Kong L, Yao XM, Jing M, Cai FY, Li XT, Ju RJ.
Liu JJ, et al. Among authors: cai fy.
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1947-1960. doi: 10.1080/21691401.2019.1615932.
Artif Cells Nanomed Biotechnol. 2019.
PMID: 31079495
Item in Clipboard
RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply.
Kong L, Cai FY, Yao XM, Jing M, Fu M, Liu JJ, He SY, Zhang L, Liu XZ, Ju RJ, Li XT.
Kong L, et al. Among authors: cai fy.
Cancer Sci. 2020 Feb;111(2):621-636. doi: 10.1111/cas.14256. Epub 2020 Jan 18.
Cancer Sci. 2020.
PMID: 31777993
Free PMC article.
Item in Clipboard
Enhanced antitumour efficiency of R8GD-modified epirubicin plus tetrandrine liposomes in treatment of gastric cancer via inhibiting tumour metastasis.
Li XT, Jing M, Cai FY, Yao XM, Kong L, Wang XB.
Li XT, et al. Among authors: cai fy.
J Liposome Res. 2021 Jun;31(2):145-157. doi: 10.1080/08982104.2020.1748647. Epub 2020 Apr 22.
J Liposome Res. 2021.
PMID: 32223361
Item in Clipboard
Cite
Cite